Clinical trials: Adjuvant Drug Therapy
NSCLC, Adjuvant Drug Therapy
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations.
- Conditions
- NSCLC, Adjuvant Drug Therapy, EGFR
- Trial name
- NCT07181499
- Testing
- Befotertinib, Pemetrexed + Carboplatin
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Resectable HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and…
- Trial name
- NCT07441460
- Testing
- KN026, HB1801, Trastuzumab
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shanghai JMT-Bio Inc.
Colorectal Cancer
Tumour Registry Colorectal Cancer
To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.
- Trial name
- TKK (NCT00910819)
- Where
- Germany
- Volunteers
- 7,000 people
- Sponsor
- iOMEDICO AG
Hypovolemic Shock
A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent
This protocol is designed to develop a novel first-in-class treatment for use in critical care and life-threatening condition of hypovolemic shock with unmet need and is of national interest.
- Trial name
- NCT05251181
- Testing
- Normal Saline, Centhaquine
- Volunteers
- 430 people
- Sponsor
- Pharmazz, Inc.
Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
- Trial name
- TroFuse-019 (NCT06312137)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
- Where
- 270 sites in United States, Argentina and 29 more
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage…
- Trial name
- KANDLELIT-013 (NCT07431827)
- Testing
- Calderasib, MK-3475A
- Where
- 120 sites in Argentina, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Neutropenia, Myelosuppression
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection.
- Conditions
- Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer
- Trial name
- MyeloConcept (NCT02692742)
- Testing
- Myelo001
- Where
- 23 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Myelo Therapeutics GmbH
Endometrial Cancer
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2…
- Trial name
- NCT07022483
- Testing
- Trastuzumab Deruxtecan, Chemotherapy
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 710 people
- Sponsor
- Daiichi Sankyo
Resectable Non-small Cell Lung Cancer
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
- Trial name
- NCT05247684
- Testing
- AK112, Carboplatin, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Adjuvant Chemotherapy
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
- Trial name
- NCT06389552
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- HK inno.N Corporation
Breast Cancer
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic…
- Trial name
- HERA (NCT00045032)
- Testing
- Herceptin
- Where
- 203 sites in Argentina, Australia and 31 more
- Volunteers
- 5,099 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Adult
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy…
- Trial name
- NCT06897228
- Testing
- PANK-003 cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shenzhen Celconta Life Science Co., Ltd.
Colon Cancer
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule.
- Trial name
- NCT05709249
- Testing
- XLJDOD compound granule
- Where
- China
- Volunteers
- 730 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Cancer-related Fatigue, Neutropenia, Malignant
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence.
- Trial name
- PG2 BEAM (NCT03314805)
- Testing
- Astragalus polysaccharides 500 mg, EC Chemotherapy
- Where
- 5 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- PhytoHealth Corporation
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal…
- Trial name
- NCT07643623
- Testing
- tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab, Ipilimumab N01
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Breast Cancer
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay
The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and…
- Trial name
- NCT01899079
- Where
- 7 sites in Spain
- Volunteers
- 217 people
- Sponsor
- NanoString Technologies, Inc.
HIV Infections
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
- Trial name
- NCT00005001
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agouron Pharmaceuticals
Gastric Cancer
RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.
- Trial name
- NCT01401075
- Testing
- mistletoe extract, doxifluridine
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Abnoba Gmbh
Breast Cancer
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
- Trial name
- NCT00556374
- Testing
- Denosumab, Non-steroidal aromatase inhibitor therapy, Zoledronic Acid
- Where
- 46 sites in Austria, Sweden
- Volunteers
- 3,420 people
- Sponsor
- Amgen
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH